Simple Summary Glioblastoma multiforme is one of the hardest-to-treat brain tumors, often
resistant to conventional treatments such as chemotherapy and radiation therapy. Despite …

Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous
population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The …

Glioblastoma multiforme (GBM) is recognized as the most common and lethal form of central
nervous system cancer. Currently used surgical techniques, chemotherapeutic agents, and …

Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, is highly
resistant to conventional radiation and chemotherapy, and is not amenable to effective …

According to the invasive nature of glioblastoma, which is the most common form of
malignant brain tumor, the standard care by surgery, chemo-and radiotherapy is particularly …

Glioblastoma multiforme (GBM) is the most common primary brain tumour, and the most
aggressive in nature. The prognosis for patients with GBM remains poor, with a median …

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults.
Standard therapeutic approaches provide modest improvement in the progression-free and …

Glioblastoma (GB) is the more frequent and malignant brain tumour. In spite of all efforts, the
median overall survival of GB patients remains approximately 15 months under therapy. The …

Highlights•Temozolomide resistance can be induced by glioblastoma cells.•Resistance to
temozolomide is caused by multiple mechanisms.•Different resistance pathways exist in …